HURAHealthcare · BiotechnologyThe 4 Wall Street analysts covering TuHURA Biosciences, Inc. hold a median 12-month price target of $8 — +301.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores TuHURA Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (74): Smaller than most of the companies we track.
Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on HURA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +301.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Aug 2026 | Citizens | Reiterates | Market Outperform | $9.00 |
| 27 Apr 2026 | Citizens | Initiates | Market Outperform | — |
| 27 Apr 2026 | Citizens | Initiates | Market Outperform | $9.00 |
| 3 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2025 | Maxim Group | Maintains | Buy | — |
| 16 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Apr 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 3 Mar 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 19 Dec 2024 | Rodman & Renshaw | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HURA appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 88% of US stocks
Cheaper than 14% of US stocks
Cheaper than 78% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 9% of US stocks
Higher than 6% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own TuHURA Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
TuHURA Biosciences held a shareholder/analystst call, and Seeking Alpha published the prepared remarks transcript of that call.
Why it matters — The transcript provides HURA watchers with the company's official prepared remarks from its shareholder/analyst call.
TuHURA Biosciences presented its late-stage immuno-oncology pipeline at the Canaccord Genuity Growth Conference, detailing an ongoing Phase III study of IFx in first-line advanced Merkel cell carcinoma, a planned AML trial for its VISTA-inhibiting antibody, and preclinical work on immune-modulating antibody-drug conjugates.
Why it matters — The presentation offers HURA watchers a clear update on the company's near-term clinical milestones and pipeline breadth.
TuHURA Biosciences reported its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The company is a Phase 3 immuno-oncology firm developing novel therapeutics aimed at overcoming resistance to cancer immunotherapy.
Why it matters — A HURA watcher would want to track these quarterly financial results and the corporate update for signs of progress in the company's immuno-oncology pipeline.
The 4 Wall Street analysts covering TuHURA Biosciences, Inc. have a median 12-month price target of $8, with estimates ranging from $6.2 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering TuHURA Biosciences, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TuHURA Biosciences, Inc. 17 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, TuHURA Biosciences, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (74 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +301.0% from the last close, and Ticker Nerd's factor model ranks TuHURA Biosciences, Inc. 17 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering TuHURA Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HURA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6.2 to $10 over the next 12 months.
TuHURA Biosciences, Inc. returned -31.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company based in Tampa, Florida, founded in 2023.
The most recent item we track (Seeking Alpha, 18 Aug 2026): "TuHURA Biosciences, Inc. (HURA) Shareholder/Analyst Call Prepared Remarks Transcript". TuHURA Biosciences held a shareholder/analystst call, and Seeking Alpha published the prepared remarks transcript of that call.
TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company based in Tampa, Florida, founded in 2023. It focuses on developing novel therapeutic technologies to help the immune system overcome resistance to cancer immunotherapy. The company’s key area of expertise is the use of innate immune agonists and personalized cancer vaccines to address both primary and acquired resistance to checkpoint inhibitors, a widely used class of immuno-oncology drugs. TuHURA Biosciences’ lead product candidate, IFx-2.0, is a personalized cancer vaccine designed to activate innate immunity and improve responses in patients whose tumors do not adequately respond to existing checkpoint inhibitor therapies. Operating within the biotechnology and pharmaceutical sector, the company concentrates its activities on a single reportable segment: advancing therapies for cancer treatment through clinical development and related research. TuHURA Biosciences plays a specialized role in the oncology market, targeting difficult-to-treat cancers where conventional immunotherapies have limited effectiveness, and contributing to the broader effort to make immune-based cancer treatments more broadly applicable across patient populations.
CEO Dr. James A. Bianco M.D. · 22 employees · United States · https://www.tuhurabio.com